CONFERENCE PROGRAM

Sunday, November 17

5:00 p.m.-7:00 p.m. OPENING KEYNOTE LECTURES
Salons E-F

5:00 p.m.-6:00 p.m. Updates in cell therapies
Crystal L. Mackall, Stanford University, Stanford, CA

6:00 p.m.-7:00 p.m. Story over time, discovery to translation, CTLA-4 and PD-1
Gordon J. Freeman, Dana-Farber Cancer Institute, Boston, MA

7:00 p.m.-9:00 p.m. OPENING RECEPTION
Back Bay

Monday, November 18

7:00 a.m.-8:00 a.m. BREAKFAST
Back Bay

8:00 a.m.-10:00 a.m. PLENARY SESSION 1: INTERSECTION OF SIGNALING PATHWAYS AND IMMUNO-ONCOLOGY
Salons E-F

Session Chair: Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA

8:00 a.m.-8:30 a.m. STK11/LKB1 and other genomic drivers of a “cold” immune phenotype in NSCLC: Implications for precision immunotherapy
John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30 a.m.-9:00 a.m. Impact of tumor-resident DC on antitumor immunity
Stefani Spranger

9:00 a.m.-9:30 a.m. Targeting the RAS-MAPK pathway to enhance immune response
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

9:30 a.m.-9:45 a.m. Development of new immune therapy combinations for ovarian cancer using genetically defined organoid platform*
Benjamin Neel, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

9:45 a.m.-10:00 a.m. Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo*
Bin-Jin Hwang, Duke University, Durham, NC

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:00 a.m.-10:30 a.m.  COFFEE BREAK
Ballroom Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 2: NOVEL CELL THERAPIES
Salons E-F

Session Chair: Katayoun Rezvani, The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 a.m.-11:03 a.m.  Optimizing T-cell receptor gene therapy for cancer
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA

11:00 a.m.-11:30 a.m.  Engineering natural killer cells for the treatment of cancer
Katayoun Rezvani

11:30 a.m.-12:00 p.m.  Understanding resistance to develop next-generation CART for lymphoid malignancies
Marco Ruella, University of Pennsylvania, Philadelphia, PA

12:00 p.m.-12:15 p.m.  Development of a transcriptomic T-cell atlas highlights the differential role of T-cell subpopulations in CAR T-cell therapy resistance*
Gregory Chen, University of Pennsylvania, Philadelphia, PA

12:15 p.m.-12:30 p.m.  Modulation of integrin CD11b as a novel therapeutic strategy against lung cancer*
Terese Geraghty, Rush University, Chicago, IL

12:30 p.m.-3:00 p.m.  LUNCH / POSTER SESSION A
Back Bay

3:00 p.m.-5:00 p.m.  PLENARY SESSION 3: ADVERSE EVENTS
Salons E-F

Session Chair: Antony Rosen, Johns Hopkins University, Baltimore, MD

3:00 p.m.-3:30 p.m.  Checkpoint inhibitor-induced autoimmune diabetes and endocrine syndromes
Kevan Herold, Yale School of Medicine, New Haven, CT

3:30 p.m.-4:00 p.m.  Immune checkpoint inhibitor-associated cardiotoxicities: Learning from mice and humans
Javid J. Moslehi, Vanderbilt University School of Medicine, Nashville, TN

4:00 p.m.-4:30 p.m.  Autoimmune rheumatic diseases and cancer: An example of natural cancer immunoediting?
Antony Rosen

4:30 p.m.-4:45 p.m.  Investigating the mechanisms of immune-related adverse events using engineered animal models*
Nikhil Joshi, Yale University, New Haven, CT

*Short talk from proffered abstract
5:00 p.m.          EVENING ON OWN

Tuesday, November 19

7:00 a.m.-8:00 a.m.        BREAKFAST
Back Bay

8:00 a.m.-10:00 a.m.           PLENARY SESSION 4: EPGENOMICS OF IMMUNO-ONCOLOGY
Salons E-F

Session Chair: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

8:00 a.m.-8:30 a.m.
Epigenetic therapy—potential efficacy for enhancing immune checkpoint therapy
Stephen B. Baylin

8:30 a.m.-9:00 a.m.
Reprogramming the epigenome for enhancing CAR T-cell antitumor efficacy
Joseph A. Fraietta, University of Pennsylvania, Philadelphia, PA

9:00 a.m.-9:30 a.m.
Molecular programs defining tumor-specific T-cell dysfunction and reprogrammability
Andrea Schietinger, Sloan Kettering Institute, New York, NY

9:30 a.m.-9:45 a.m.
Disrupting enhancers within the core epigenetic program of exhaustion improves T-cell responses and enhances tumor control*
Debattama Sen, Dana-Farber Cancer Institute, Boston, MA

9:45 a.m.-10:05 a.m.
Epigenetic deregulation in LSD1-deficient luminal mammary tumor cells leads to their increased metastasis via reprogramming of the immune microenvironment*
Zhe Li, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

10:00 a.m.-10:30 a.m.       COFFEE BREAK
Ballroom Foyer

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:30 a.m.-12:30 p.m. PLENARY SESSION 5: IMAGING AND NEW TECHNOLOGIES
Salons E-F

Session Chair: Mohammad Rashidian, Harvard Medical School, Cambridge, MA

10:30 a.m.-11:00 a.m. Noninvasive imaging of immune responses
Mohammad Rashidian

11:00 a.m.-11:30 a.m. Whole-body PD-L1 and PD-1 PET: First-in-human experience
David W. Leung, Bristol-Myers Squibb, Princeton, NJ

11:30 a.m.-12:30 p.m. AI-powered pathology for precision medicine
Andrew H. Beck, PathAI, Boston, MA
(not eligible for CME credit)

12:00 p.m.-12:15 p.m. Irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic antitumor immunity*
Irving Allen, Virginia Tech, Blacksburg, VA

12:30 p.m.-2:30 p.m. LUNCH ON OWN

2:30 p.m.-4:30 p.m. PLENARY SESSION 6: TUMOR EVOLUTION AND THE TUMOR MICROENVIRONMENT
Salons E-F

Session Chair: Christina Leslie, Sloan Kettering Institute, New York, NY

2:30 p.m.-3:00 p.m. The impact of tumor microenvironment on clonal evolution in cancer
Samra Turajlic, The Francis Crick Institute, London, United Kingdom

3:00 p.m.-3:30 p.m. Myeloid cell control of tumor immunity
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

3:30 p.m.-4:00 p.m. Chromatin state and scRNA-seq analysis defines a common differentiation trajectory towards T-cell exhaustion
Christina Leslie

4:00 p.m.-4:15 p.m. Loss of PD-1 promotes antitumor immunity by improving functions of both PD-1+ and PD-1- CD8+ T cells in the tumor microenvironment*
Kristen Pauken, Harvard Medical School, Boston, MA

4:15 p.m.-4:30 p.m. Active and quiescent tertiary lymphoid structures, differentiated using FOXP1 expression, play a role in immunity to breast cancer*
Pushpamali De Silva, Institut Jules Bordet, Brussels, Belgium

4:30 p.m.-7:00 p.m. RECEPTION / POSTER SESSION B
Back Bay

*Short talk from proffered abstract
Wednesday, November 20

7:00 a.m.-8:00 a.m.  BREAKFAST  
Arlington & Fairfield

8:00 a.m.-10:00 a.m.  PLENARY SESSION 7: INTERACTION BETWEEN THE MICROBIOME AND IMMUNITY, SYSTEMIC AND LOCAL RESPONSES  
Salons E-F  
Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:30 a.m.  Colorectal cancer and the microbiota  
Wendy S. Garrett, Harvard T.H. Chan School of Public Health, Boston, MA

8:30 a.m.-9:00 a.m.  The unsuspected role of gut microbiota in cancer therapies: Antigen mimicry between intestinal phage and tumor antigens  
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

9:00 a.m.-9:30 a.m.  The role of the microbiome in response and toxicity to cancer therapy  
Jennifer A. Wargo

10:00 a.m.-10:30 a.m.  COFFEE BREAK  
Ballroom Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 8: INTERFACE OF GENETICS, ANTIGENS, AND IMMUNOOncology, INCLUDING VACCINES, ADJUVANTS, AND BIOMARKERS  
Salons E-F  
Session Chair: Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY

10:30 a.m.-11:00 a.m.  T cells as a drug for the personalized immunotherapy of cancer  
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

11:00 a.m.-11:30 a.m.  Tumor-intrinsic drivers of response and resistance to checkpoint blockade in MRD tumors  
Luis A. Diaz

11:30 a.m.-11:45 a.m.  Antigen dominance hierarchies shape tumor T cell phenotypes and immunotherapy responses*  
Megan Burger, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

11:45 a.m.-12:00 p.m.  Genomic landscape of immunotherapy resistance in lung cancer*  
Denise Lau, Tempus, Chicago, IL

*Short talk from proffered abstract
CONFERENCE PROGRAM

12:00 p.m.-12:15 p.m.  Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination*
Joseph Antonios, Yale School of Medicine, New Haven, CT

12:15 p.m.-12:30 p.m.  Emergence of quality metrics for neoantigens: Dissimilarity to the self-proteome as a novel determinant of immunogenicity*
Lee Richman, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

12:30 p.m.  CONCLUDING REMARKS
Salons E-F

*Short talk from proffered abstract